Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Brazilian university designs new analgesic with in vivo activity

Oct. 20, 2011

Phase II study assessed combination therapy containing rilotumumab in cancer

Oct. 20, 2011

Vandetanib/bicalutamide combination trial does not meet primary endpoint

Oct. 20, 2011

Exparel leads to sustained release of bupivacaine

Oct. 20, 2011

Analyses focus on cardiovascular risk with naltrexone/bupropion

Oct. 19, 2011

U.S. universities assess CDME in model of cystinuria

Oct. 19, 2011

Orantinib advances through studies in NSCLC and breast cancer

Oct. 19, 2011

Trial determines phase II doses of ixabepilone/cisplatin combination regimen in NSCLC

Oct. 19, 2011

Interim first-in-human data released on two c-Met inhibitors

Oct. 19, 2011

ABI-007 advances through trial in gastric cancer

Oct. 18, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...